Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 6/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970366 | 0.83 | DPP4 (0.53) | DPP4DPP8DPP9DPP7LRRK2 | |
| SCHEMBL3134930 | 0.75 | CYP8B1 (0.54) | DPP4DPP8DPP9DPP7NR1H2 | |
| SCHEMBL16790052 | 0.74 | DPP4 (0.32) | DPP4DPP8DPP9DPP7NR1H2 | |
| SCHEMBL5935898 | 0.72 | PDK1 (0.45) | NR1H2CYP8B1GPR119 | |
| SCHEMBL16790031 | 0.71 | PARP1 (0.44) | NR1H2CYP8B1MAPTGPR119RORC | |
| SCHEMBL16790035 | 0.70 | CYP8B1 (0.38) | NR1H2CYP8B1GPR119RORC | |
| SCHEMBL16812695 | 0.70 | CYP8B1 (0.40) | NR1H2CYP8B1GPR119RORC | |
| SCHEMBL24694593 | 0.68 | CYP8B1 (0.42) | CYP8B1MAPTGPR119HDAC4 | |
| SCHEMBL19877142 | 0.68 | HPGD (0.54) | CYP8B1 | |
| SCHEMBL3067458 | 0.68 | AR (0.50) | CYP8B1MAPTGPR119USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255106-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as PARP-1 inhibitors | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-02-09 | — | — | US | disclosed |
| US-20150166544-A1 | PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD. (CN) | 2015-06-18 | — | — | US | disclosed |
| US-20150166544-A1 | PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD. (CN) | 2015-06-18 | — | — | US | disclosed |
| EP-2881395-A1 | PIPERAZINOTRIZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166544-A1 | PIPERAZINOTRIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN DRUG PREPARATION | PARP1, PARP11, PARP8 | DPP4 552/4885DPP8 233/4885DPP9 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.